×
About 23,303 results

ALLMedicine™ Lymphoma Center

Research & Reviews  8,921 results

CD30 + Primary intestinal T-cell lymphoma (unclassified) masquerading as chronic inflam...
https://doi.org/10.1186/s13000-022-01237-0 10.1002/hon.2317 10.1182/blood-2013-07-512830 10.1182/blood-2010-08-302737 10.1182/blood-2009-07-231324 10.1038/leu.2013.41 10.1007/s00277-019-03791-y 10.1016/j.pathol.2019.10.001 10.1182/blood-2012-11-466839 10.1016/S0140-6736(18)32984-2 10.4143/crt.2019.198
Diagnostic Pathology; Osmani K, Shah E et. al.

Jun 26th, 2022 - Primary intestinal T-cell lymphomas are uncommon malignancies that pose a diagnostic dilemma, because the clinical features and imaging findings commonly overlap with those encountered in inflammatory bowel diseases. The current clinical case repo...

C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced...
https://doi.org/10.2967/jnumed.122.264207
Journal of Nuclear Medicine : Official Publication, Socie... Buck AK, Grigoleit GU et. al.

Jun 24th, 2022 - Objectives: C-X-C motif chemokine receptor 4 (CXCR4)-targeted radioligand therapy (RLT) has already been applied to advanced blood cancers, such as multiple myeloma or diffuse large B-cell lymphoma. We herein present a series of patients with adva...

Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bort...
https://doi.org/10.3390/curroncol29060328
Current Oncology (Toronto, Ont.); Roche KC, DeRosa PA et. al.

Jun 24th, 2022 - Standard treatment regimens for the management of patients with refractory splenic marginal zone lymphoma (SMZL) are currently unavailable. Here, we report a case of SMZL, which, after failing multiple therapeutics, demonstrated an impressive clin...

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase II...
https://doi.org/10.1182/blood.2021014270
Blood Ferrero S, Grimaldi D et. al.

Jun 24th, 2022 - Minimal residual disease (MRD) analysis is a known predictive tool in mantle cell lymphoma (MCL). We describe MRD results from the Fondazione Italiana Linfomi phase III MCL0208 prospective clinical trial assessing lenalidomide maintenance vs obser...

see more →

Guidelines  21 results

UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic La...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894347
British Journal of Haematology; Turton P, El-Sharkawi D et. al.

Nov 23rd, 2020 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast sy...

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Gu...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-Associated Anap...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106983
Journal of Clinical Oncology : Official Journal of the Am... Jaffe ES, Ashar BS et. al.

Feb 12th, 2020 - To provide guidelines for the accurate pathologic diagnosis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the preoperative evaluation of the patient with suspected BIA-ALCL, and the pathologic evaluation of the capsulecto...

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical ...
https://doi.org/10.6004/jnccn.2020.0006
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.

Feb 6th, 2020 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues. Treatment of CLL/SLL has evolved significantly in...

see more →

Drugs  78 results see all →

News  297 results

FDA Okays Liso-cel for Second Line in Large B-cell Lymphoma
https://www.medscape.com/viewarticle/976230

Jun 27th, 2022 - Lisocabtagene maraleucel, also known as liso-cel (Breyanzi), has been approved by the Food and Drug Administration for the second-line treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL). This expanded indicati...

Hodgkin Lymphoma Clinical Practice Guidelines (NCCN, 2022)
https://www.medscape.com/viewarticle/972832

Apr 29th, 2022 - Guidelines for the management of Hodgkin lymphoma were published in April 2022 by the National Comprehensive Cancer Network (NCCN) in Journal of the National Comprehensive Cancer Network (JNCCN).[1] Radiation therapy (RT) delivery techniques that ...

FDA Panel: Concerns Over PI3K Inhibitors in Blood Cancers
https://www.medscape.com/viewarticle/972610

Apr 22nd, 2022 - Federal advisers have unanimously called for randomized trials for a class of drugs used in the treatment of blood cancers, citing concerns about toxicities of these medicines. The US Food and Drug Administration (FDA) called on advice from its On...

Zanubrutinib Shows Worth Against Standard CLL Drugs
https://www.medscape.com/viewarticle/972075

Apr 13th, 2022 - A new treatment option may soon be available for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Zanubrutinib (Brukinsa), an irreversible, next-generation Bruton tyrosine kinase (BTK) inhibitor, is designed to mi...

First-Line Axi-cel Therapy Effective in High-Risk Large-B-Cell Lymphoma
https://www.medscape.com/viewarticle/970882

Mar 25th, 2022 - NEW YORK (Reuters Health) - New research supports the use of axicabtagene ciloleucel (axi-cel) as first-line treatment for patients with high-risk large-B-cell lymphoma (LBCL). Axi-cel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-c...

see more →

Patient Education  4 results see all →